4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Embolism by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 188 ongoing clinical trials involving Pulmonary Embolism
Of the 188 trials,100 trials are in Phase III
Furthermore, 41 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Embolism by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pulmonary Embolism, a cardiovascular indication. The largest number of ongoing clinical trials for Pulmonary Embolism is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Pulmonary Embolism-related drug trials.

Ottawa Hospital Research Institute: The leading ongoing Pulmonary Embolism related clinical trial sponsor

Ottawa Hospital Research Institute is the top sponsor for Pulmonary Embolism-related ongoing clinical trials.

Tianjin Pharmaceuticals Group Co Ltd, Arianna Anticoagulazione Foundation, and University Hospital Inselspital Berne are among other notable clinical trial sponsors involved in Pulmonary Embolism. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pulmonary Embolism

Apixaban (Eliquis), Rivaroxaban (Xarelto), and Dabigatran etexilate mesylate (Pradaxa, Prazaxa, Pradaxar) are among the key marketed drugs involving Pulmonary Embolism.

Apixaban (Eliquis) is a phenylpiperidine derivative, acts as antithrombotic or anticoagulant agent. Apixaban functions via Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6) Inhibitor mechanism of action. It is formulated as tablets and film-coated tablets for oral route of administration. Eliquis is indicated to reduce the risk of stroke, systemic embolism in patients with non valvular atrial fibrillation and for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). Apixaban was first approved in 2011 and is marketed globally including the US, the UK, France, and Australia by several giant pharma including Bristol-Myers Squibb Co, and Pfizer Inc.

Rivaroxaban (Xarelto) belongs to the class of antithrombotic agents.  It functions via Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6) Inhibitor mechanism of action.  It is formulated as film-coated tablets, tablets, granules/powder for suspension and suspension for oral route of administration. Rivaroxaban is marketed for the treatment of Pulmonary Embolism and several other indications including Venous Thromboembolism, Congenital Heart Disease, Stroke, Ischemic Stroke, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pulmonary Embolism, Arterial Thromboembolism, Deep Vein Thrombosis (DVT), and Thromboembolism. Rivaroxaban was first approved in 2008 and is marketed globally including the US, the UK, France, and Australia by several giant pharma including Bayer Inc, and Janssen Pharmaceuticals Inc.